Proposal in Brazil to exempt medicines from tax

INICIO/Políticas y legislación | Posted 21/03/2014 post-comment0 Post your comment

The Brazilian Government announced on 9 February 2014 that it is setting up a committee to evaluate whether to exempt medicines from tax in the country.

119 MD002332

The joint committee will be set up in order to speed up the analysis process and provide an answer on the Proposal (PEC 301/13), which would ban taxes on pharmaceutical drugs and ingredients used in production and marketing.

The proposal on tax exemption of medicines was organized by the Parliamentary Front for the Tax Exemption of Medicines, with the campaign being organized by the Brazilian Association of Pharmacies and Drugstores Networks (Abrafarma) in partnership with the Association of Pharmaceutical Industry Research (Interfarma).

The proposal was introduced to the Brazilian House of Representative as a constitutional amendment, by Mr Francisco Chagas. The following arguments have been stated as reasons for the introduction of this proposal:

• To put an end to different tax rates on pharmaceuticals between different states in Brazil
• To encourage the creation of an industrial policy to strengthen the pharmaceutical sector in Brazil (national production is currently less than 10%)
• To generate technology, jobs and investment
• To provide savings to patients when buying medicines, estimated at BRL 19 billion

Taxes on pharmaceuticals in Brazil are currently estimated by Abrafarma and Interfarma to be around 33.9%, which represents more than a third of the final price paid by consumers.

Related articles

Confusion exists in Brazil over generics 

Brazil to designate medicamentos similares as interchangeable 

Medicines spending in Brazil

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
USA BIOSIM Act introduction
02 AA010638
INICIO/Políticas y legislación Posted 17/09/2021
MERCOSUR: Nuevo arancel para biológicos y biosimilares sin capital latina
138 AA011155
INICIO/Políticas y legislación Posted 03/09/2021
Nuevo tratado comercial entre México, Estados Unidos y Canadá
62 MD001919
INICIO/Políticas y legislación Posted 27/08/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010